Feed SNGX
SN

Soligenix, Inc.

SNGX · NASDAQ

$0.36 +1.20% (+$0.00)
1M -4.51%
Market Cap $5.40M
P/E Ratio -
Div. Yield -
ROE 181.03%

Bulios Fair Price

$0.18

50.5% downside

Trenutna cena

$0.36

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica SNGX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
100 /100
Cheap
P/B 0.81x
P/E N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 151.39%
ROE 181.03%
ROA 97.52%
Debt
100 /100
Low
Debt/Equity 0.05x
Current ratio 2.77x
Int. coverage N/A
Stability
44 /100
Moderate
Beta 1.92x
EPS volatility 14.37%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o SNGX
Online

O podjetju

Soligenix, Inc. (SNGX) is a biopharmaceutical company that focuses on the development and commercialization of drug products for the treatment of a range of diseases, including rare diseases and serious medical conditions. The company specializes in utilizing biotechnology and pharmacology for the development of therapeutic solutions. Soligenix also emphasizes research and clinical trials to confirm the efficacy and safety of its products. Their therapeutic innovations have the potential to help patients suffering from challenging-to-treat conditions. Shares of Soligenix, Inc. (SNGX) can be an interesting choice for investors tracking the biopharmaceutical sector and the development of therapeutic treatments.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Christopher J. Schaber

Employees

14

Headquarters

Princeton

Prihajajoči dogodki

06 NOV.

Earnings

Upcoming earnings report

53d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.